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Structure-based inhibitor screening of natural  products against NSP15 of SARS-
CoV-2 revealed Thymopentin and Oleuropein as potent inhibitors
Abstract: Coronaviruses are enveloped, non-segmented positive-sense RNA viruses that
have the largest  genome among RNA viruses. The genome contains  a large replicase
ORF encodes nonstructural proteins (NSPs), structural and accessory genes. NSP15 is a
nidoviral  RNA uridylate-specific  endoribonuclease  (NendoU) has  C-terminal  catalytic
domain.  The  endoribonuclease  activity  of  NSP15  interferes  with  the  innate  immune
response  of  the  host.  Here,  we  screened  Selleckchem  Natural  product  database  of
compounds against the NSP15, Thymopentin  and Oleuropein showed highest  binding
energies. The binding of these molecules was further validated by Molecular dynamic
simulation  and  found  very  stable  complexes.  These  drugs  might  serve  as  effective
counter molecules in the reduction of virulence of this virus. Future validation of both
these inhibitors are worth consideration for patients being treated for COVID -19. 
Aims: NSP15 of SARS-CoV-2 is vital for its life cycle and replication; hence, it is an
attractive target for structure-based drug design of anti-SARS drugs. Worldwide research
is underway, yet, FDA has not approved any vaccine for its treatment. Infection caused
by this virus spreads through human-to-human contact, and has taken a toll of several
human lives worldwide. As per the WHO guidelines, lock-down was implemented as a
precaution to control the spread of the disease. The outbreak of COVID -19 raised global
concerns due to its virulence, and initiated emphasize on the urgent need to find effective
drugs  for  the  treatment.  Methods: The  structure-based drug designing approach  was
utilized to find anti-SARS drugs.  Key findings: We performed virtual screening of the
Selleckchem Natural product database of compounds against the NSP15 of SARS-CoV-
2. We have identified Thymopentin (FDA approved drug), Ginsenoside and Oleuropein
with high clinical potential against SARS-CoV-2.  Significance: Further validations are
necessary  to  test  the  efficacy  and  safety  of  these  drugs  to  be  used  for  efficient
therapeutics against the COVID -19. 
Keywords:  Drug  designing,  Virtual  screening,   Severe  Acute  Respiratory  Syndrome
Coronavirus 2 (SARS-CoV-2), Natural products
Introduction:
Severe  Acute  Respiratory  Syndrome Coronavirus  2 (SARS-CoV-2) is  also known as
novel  coronavirus  of  2019  (COVID  -19)  [1].  SARS-CoV-2  causes  a  wide  array  of
respiratory, gastrointestinal, and neurological diseases in humans [2-4]. Coronavirus has
the  largest  genomes of  the  known RNA viruses,  ranging ~30 kb [5],  which encodes
Structural proteins, S (spike), E (envelope), M (membrane), [6, 7] and Non-structural N
(nucleocapsid) proteins [8, 9]. Non-structural protein 15 (NSP15) is an endoribonuclease
that cleaves 3’ of uridylate through a ribonuclease A (RNase A) [10, 11]. Though it is not
required for viral replication, but it mediates evasion of host dsRNA sensors [12, 13]. The
structure of SARS-CoV-2 NSP15 protein is very similar  to other Coronavirus NSP15
monomers,  consisting  of  mainly  three  regions:  the  N-terminal  domain,  a  subsequent
middle  domain,  and  a  catalytic  C-terminal  nidoviral  RNA  uridylate-specific
endoribonuclease domain. The active-site residues of NSP15 indicate His262, His277,
and  Lys317  are  conserved  across  the  entire  endoribonuclease  family  and  play  an
important role in enzyme catalysis [13]. The mutant viruses of NSP15 causing apoptotic
cell death and significant reduction of replication in macrophages [14, 15].  SARS-CoV-2
has infected more than 14 million people and caused over 532,340 deaths worldwide
(https://www.who.int). The rapidly increasing numbers of the infected patients, prompted
the  World  Health  Organization  to  declare  a  state  of  global  health  emergency  to
coordinate the scientific and medical efforts to expedite the development of a cure for the
patients. 
NSP15 is important for disease progression and thus, is a potential target for drug and
vaccine development. Till  date, no targeted treatment molecule has been developed to
prevent the COVID-19 infection. Recently  in-silico studies have reported the possible
inhibitors  against  NSP15 [16-20].  Remedesvir  and Favipiravir  are the latest  approved
drugs for the treatment  of COVID-19 [21, 22]. However,  these drugs are not able  to
control the novel Coronavirus outbreak and the subsequent pandemic [23]. In order to
design  specific  inhibitors  against  the  Non-structural  protein  15 (NSP15), Libraries  of
Selleckchem Natural products (https://www.selleckchem.com/screening/natural-product-
library.html) were  chosen  for  Virtual  screening  [24-26].  Top  10  compounds  were
selected based on their binding affinities. Further, Molecular dynamic simulation [25-27]
was used to analyze the stability and the inter-molecular interactions between the NSP15
and the lead compounds.
Materials and methods:
The crystal structure of the Non-structural protein 15 (NSP15) was retrieved from the
RCSB Protein Data Bank (entry code  6W01) and, was used as target for our modeling
studies.  Starting  structure  of  NSP15  for  docking  studies  was  prepared  with  Protein
Preparation Wizard [28]. The process adds hydrogen, neutralizes appropriate amino acid
chains,  and  relieves  steric  clashes.  Also,  it  performs  a  series  of  restrained,  partial
minimizations on the co-crystallized structure, each of which employs a limited number
of minimization steps. It is not intended to minimize the system completely. In our study,
the minimization (OPLS 2003 force field) [28] was stopped when RMSD of the non-
hydrogen atoms reached 0.30 Å, which is the default specified limit.
Selleckchem  Natural  product  libraries  with  about  900,000  unique  molecules  and
1,350,000  drug-like  and  lead-like  screening  compounds  were  chosen  for  virtual
screening. Libraries were prepared by energy minimization of 100 steps with the Ligprep
module of Schrodinger [29]. 
Experimental studies on NSP15 have revealed that His235, His250, and Lys290 [10] are
the critical residues for catalysis that are located in the C-terminal domain of the enzyme. 
Docking studies [30-34] were performed using GOLD [35], and the protein was kept as a
rigid molecule, and the number of Genetic Algorithm (GA) runs was set to 10 runs per
ligand with the default search algorithm parameters. GOLD score was then used as the
final scoring method.
In order to estimate the accuracy of binding affinity of GLIDE [36], MOE docking [31]
and Auto-dock [37] were used for cross-docking analysis. 
In the Glide-docking [36], the prepared structure was used to generate the receptor grid
and no scaling was done for the Van der Waals radii of nonpolar receptor atoms. An
enclosing  box  was  used  as  the  docking  space,  centered  on  the  His235,  His250,  and
Lys290, catalytic triad using the crystallographic position as their reference; the ligand
diameter midpoint box was set to the default value (10 Å). Docking experiments were
performed using 0.80 to scale the VdW radii of the nonpolar ligand atoms with a charge
cutoff of 0.15. Poses were discarded as duplicates if both, the rms deviations in the ligand
(all atoms) was less than 0.5 Å and maximum atomic displacement was less than 1.3 Å.
At most, 10 poses per ligand were retained. GlideScore XP  [36] was used as the scoring
method to finalize the screening. 
For MOE docking [31], the protein was kept as a rigid entity, and a maximum of 10
conformations  for  each  ligand  was  taken  using  the  default  parameters  of  MOE with
Triangle Matcher placement. The top ranked conformations of NSP15 with the lead-like
compounds  docked  conformations  was  stored.  On  the  basis  of  MOE  scoring
{Generalized-Born Volume Integral/Weighted Surface Area (GBVI/WSA)}, binding free
energy calculation in the S field denotes the score. The GBVI/WSA is a scoring function
that estimates the free energy of binding of the ligand for a given pose. For all scoring
functions,  lower  scores  indicate  the  more  favorable  poses.  Top  ranked  docked
conformations of the lead-like compounds were selected for further evaluation. 
In the AutoDock 4.2 [37], empirical free energy function and the Lamarckian Genetic
Algorithm were used for  all  the  docking calculations  and the AutoDockTools  (ADT)
package [28] was used to generate input files and to analyze the results. The NSP15 was
set to be rigid and in small molecules all the torsional bonds were kept free during the
docking process. The solvent molecules were not considered during the docking process.
A cubic grid box of 60 Å size (x62.520, y73.546, z29.278) with a spacing of 0.375 Å and
grid maps was created. The ten best solutions based on the docking scores were retained
for further investigations. XSCORE [38] has been used to estimate the binding affinity of
the molecules. Interactions between the protein and the compounds were calculated using
the  Discovery  Studio  program  [39].  All  Molecular  dynamic  simulation  (MD)  were
performed with GROMACS [40], using the GROMOS 53A6 force field [40]. Further
details of the simulation protocol have been used as described previously [25-27]. 
Results and Discussion: 
Superposition  of  NSP15  with  all  other  available  coronavirus  homologues  reveals
structural conservation amongst these proteins. The structure of the SARS-CoV-2 yielded
a RMSD of 0.4 Å and 0.9Å with SARS-CoV, and Murine-CoV NSP15, respectively
(Figure 1). Comparison of all the 3 structures showed some deviations in the active site
residues as marked in Figure 2. These conformational changes at the active site of NSP15
need to be considered carefully during the inhibitor design. 
Figure  1:  Superimposition  of  NSP15  at  the  active  site  from various  organisms,
SARS- CoV-2, SARS-CoV and Murine-CoV showed that the structures are very
similar to each other. SARS- CoV-2 depicted in red,  SARS-CoV depicted in green,
Murine-CoV, depicted in cyan
Figure  2:  Residues are  shown in the drug-binding region.  These conformational
changes observed at the active site residues are highlighted. SARS- CoV-2 depicted
in red, SARS-CoV depicted in green, Murine-CoV, depicted in cyan
NSP15 is a known antiviral drug target and its active site constitutes the catalytic residues
His 235, His 250, Lys 290. In order to find drugs that could potentially inhibit NSP15, the
crystal Structure of NSP15 endoribonuclease from SARS-CoV-2 in complex with citrate
at 1.9 Å (PDB ID: 6W01) was used as the target to perform Virtual screening with the
Selleckchem Natural Product database containing 28,228 small molecules. His 235, His
250, Lys 290, Thr 341, Tyr 343, and Ser 294 comprises the active site. Among those
residues, His 235, His 250, and Lys 290 form the catalytic triad (Figure 2). 
GOLD [35] was used to perform virtual screening. Further, multiple docking algorithms
using  GLIDE  [36],  Auto-dock  [37]  and  MOE  [31]  docking  ensures  the  accurate
prediction of binding affinities.  These docking algorithms are the most commonly used
to estimate the binding affinity and binding pose of the inhibitor and the enzyme. The
identification  of  the  inhibitors  for  various  targets  using  these  docking  and  virtual
screening algorithms obtained high successful rate based on our previous studies [24-27].
Therefore, we used all of the above-mentioned software to dock the Selleckchem Natural
Product  database  (https://www.selleckchem.com/screening/natural-product-library.html)
of 28,228 small molecules against NSP15 in order to evaluate their binding affinities.
Also, we docked the previously reported ligands [16-20, 41, 42], Remedesvir [21, 22] and
Lopinavir [21, 22] as reference.
The  top-ranked  docked  molecules  were  sorted  according  to  their  GOLD score  [35],
GLIDE score  [36],  Auto-dock free  energy of  binding [37]  and MOE score  [31]  and
XSCORE [38]. These criteria were applied for the higher binding affinity compounds
against NSP15 enzyme. Mainly the mode of binding and their potential interactions with
the  active  site  residues,  and  the  estimated  binding  affinities  were  the  major  factors
considered (Table 2) (Figure 3 & Figure 4). 
We have chosen the top 10 compounds (Figure 5) for further analysis since these drug
compounds  yielded  higher  binding affinities  (Table  1).  The  top  10  compounds  were
found to fit tightly into the hydrophobic binding pocket and in close interaction with the
catalytic triad. Among these compounds, five compounds show higher binding affinities
compared to the reported compounds for NSP15 (Table S1) (Figure S1).  The toxicity
analysis does not indicate any adverse effects for the top compounds (Table S2), and can
be thus taken forward for further studies.
After the docking studies, the Molecular dynamic simulation [25-27] was performed for
the  top  five  screened  compounds  (Thymopentin,  Ginsenoside,  Oleuropein,  Akebia
Saponin  D  and  Keampferitrin),  to  understand  the  binding  stability  of  the  docked
complexes. The simulations were performed for a 100 ns to analyze the conformational
stability of these complexes. 
Figure 3: Modes of binding and its interactions of the top five-inhibitor leads with
NSP15
Figure  4:  Modes  of  binding  and  its  interactions  of  the  top  inhibitor  leads  with
NSP15
No Protein Ligands GOLD 
score
GLIDE score
kcal/mol
Auto-dock
kcal/mol
MOE
kcal/mol
X-Score
kcal/mol
-logKd
1. NSP15 Thymopentin 86.59 -11.030741 -9.7 -12.811 -9.63 8.49
2. NSP15 Oleuropein 84.69 -10.960358 -8.5 -17.1605 -8.70 7.50
3. NSP15 Ginsenoside 83.83 -9.856758 -8.0 -14.4559 -8.92 6.54
4. NSP15 Kaempferitrin 83.32 -9.17588 -7.0 -17.3375 -9.04 7.63
5. NSP15 Rhoifolin 82.14 -9.231593 -6.5 -12.1433 -8.43 7.18
6. NSP15 Demeclocyclin
hydrochloride
81.71 -8.553255 -8.1 -18.0979 -8.15 6.98
7. NSP15 Akebia
Saponin D
80.17 -8.173799 -7.5 -12.3011 -8.89 7.25
8. NSP15 Liensinine 79.31 -7.752487 -7.7 -12.4259 -8.10 6.67
9. NSP15 Fidaxomicin 79.14 -10.166778 -7.6 -15.6436 -8.58 7.10
10. NSP15 Amikacin
hydrate
73.85 -8.754372 -7.0 -12.7334 -7.80 6.12
Table 1: Screening of NSP15 with the top-10 inhibitors and their estimated binding 
affinities
Figure  5:  The  chemical  structure  of  the  top  scoring  compounds  identified  from
Virtual screening.
Molecular  dynamic  simulation   [25-27]  is  considered  to  be  a  reliable  approach  with
greater insight into the dynamic behavior of proteins and that of the ligand conformations
[25-27]. The simulations provide detailed information to better understand the motions of
the individual atoms as a function of time and properties of the molecules. We carried out
a  100 ns  MD simulation  to  accurately  predict  the  binding  stability  on  the  identified
compounds against NSP15 as explained in the Methods section. We have studied the root
mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration
(Rg), solvent accessible surface area (SASA), and hydrogen bonding interactions (NH)
between the NSP15 alone as well as in complex with the top five inhibitors. A total of 6
independent simulations were carried out, each with 100 ns simulation time. 
According to the RMSD (Root-Mean-Square Deviation) calculation, shown in Figure 5,
it can be seen that all the complexes tend to achieve equilibrium after 10 ns and lead to a
stable trajectory throughout the simulation.  We found that  Ginsenoside, Kaempgeritrin
and  Akebia  saponin  D  complexes  with  NSP15  tend  to  reach  a  higher  equilibrium
compared to the native, and remained distinguished throughout the simulation, resulting
in  the  RMSD  of  0.1  to  0.75  nm.  The  RMSD  trajectories  for  the  Thymopentin  and
Oleuropein complexes with NSP15 observed a lower equilibrium compared to the native
with minor difference in their trajectory that leads to a stable equilibrium through the end
of the simulation,  suggesting that the complexes stabilized themselves (Figure 6A). The
higher RMSD obtained for all the complexes were limited to 0.75 nm that demonstrates
the stable trajectories and provided us with an appropriate basis for further investigation.
(Figure 6A). 
Figure 6: MD simulation results for NSP15 with ligands. (A) RMSD analysis for the
model system NSP15 protein alone and protein in complex with hits compounds  (B)
Radius of gyration plot for NSP15 and top5 compounds complexes. (C) RMSF plot
for NSP15 and top5 hit compounds complexes D) SASA plot for NSP15 and top5 hit
compounds complexes
In  order  to  observe  the  ligand  induced  conformational  changes  of  the  protein,  we
calculated the C-RMSF to observe the overall flexibility of the atomic positions in the
trajectory for the native and the protein-ligand complexes (Figure 6B). The flexibility of
the residues in each of the protein-ligand was analysed by means of RMSF, where the
higher  RMSF value  describes  the  higher  flexibility.  According to  Figure  5B,  Akebia
Saponin D and Keampgertrin  produced higher fluctuations in the residues positions 40,
90, 110, 200, 250, 275, 290, 310, and 320 during the simulation, while low fluctuations
were  observed for  Ginsenoside,  thymopentin,  Oleuropein,  except  at  the  150th residue
position.  Overall,  the  RMSF  result  showed  that  the  Ginsenoside,  Thymopentin,  and
Oleuropein  complexes were more stable than the  Akebia Saponin D and Keampgertrin
complexes. (Fig. 6B).
The Rg (radius of gyration) is used to calculate the compactness of a protein (Figure 5C).
The radius of gyration is the root mean square distance of a particular atom or group of
atoms with its center of mass. The overall NSP15 structure at various time points during
the trajectory can be analyzed for the competence, shape, and folding in the Rg plot (.
(Figure 5C). Akebia Saponin D-NSP15 complex showed a higher deviation with a Rg
score of 2.4 nm. All the other compounds, Ginsenoside, Thymopentin, Oleuropein, and
Keampgertrin had an aggregate Rg score of 2.2 nm in a decreasing trend  followed by
stabilisation after 40 ns towards the end of the simulation (Figure 6C).
We have measured the compactness of the hydrophobic core by analyzing the
changes  in  SASA.  As  shown  in  Figure  5D,  an  increase  of  the  SASA  values  were
observed  for  Akebia  Saponin  D  and  Keampgertrin after  10 ns  of  simulation  time
maintained till the end, while the Ginsenoside, Thymopentin, and Oleuropein complexes
showed stable conformation throughout the simulations. As higher SASA value leads to
an increased exposure, there was loss of hydrophobic contact between the protein-ligand
complexes (Figure 6D). 
Finally,  the  number  of  hydrogen  bonds  for  each  of  the  protein  complex  was
calculated during the simulation. An increase of hydrogen bonds, Van der Waals, and
electrostatic  interactions  were  observed  for  Ginsenoside,  Thymopentin,  Oleuropein
compounds, while Akebia Saponin D and Keampgertrin formed lesser interactions (Fig. 3
& Fig. 4). 
The  top-ranked  compound  obtained  from  the  virtual  screening  is  the  FDA
approved drug, Thymopentin (Table 1). Thymopentin binds to the active site of NSP15
endoribonuclease and may potentially block the replication of virus. Thymopentin (TP5)
is a synthetic pentapeptide (Arg-Lys-AspVal-Tyr) belongs to the native thymic hormone
thymopoietin [43]. Thymopentin has been suggested for the treatment of autoimmune
diseases,  and including chronic  lymphocytic  leukemia  [44],  rheumatoid  arthritis  [45],
cancer immunodeficiency [46], acquired immunodeficiency syndrome (AIDS) [47], and
chronic  heart  failure  [48].  Thymopentin  [45]  is  also  known  to  be  an  effective
immunomodulatory agent and helps to improve immunological condition for patients.
The  second  compound,  Oleuropein  showed  strong  binding  with  NSP15
endoribonuclease.  Oleuropein is  a  phenylethanoid,  mainly  found  in  the  olive  leaves.
Oleuropein suppresses cancer cells by activating the gerosuppressor AMPK by reduction
of  growth  in  human  primary  cells  leads  to  several  transcriptomic signatures  [49].
Oleuropein helps  reducing  colonic  microflora by  Hydroxytyrosol  (HT)  and  is  mainly
present in the olive leaf and olive oil. Oleuropein is known to be a potent antioxidants
observed in nature to date [50]. 
The third rank compound, Ginsenoside also binds tightly to the catalytic center of NSP15
structure.  Ginsenosides are  the  natural  products of steroid glycosides and triterpene
saponins. Ginsenosides family consists of the oleanane family and is pentacylic in nature,
composed  of  a  five-ring  carbon  skeleton  [51]. Ginsenosides  have  shown  diverse
pharmacological and biological properties, such as antitumorogenic, anti-inflammatory,
antioxidant, and inhibitor of cell apoptosis.
The  top  ranking  compound  Thymopentin  [43-48],  FDA  approved  drug  is  currently
available in the market. The other two compounds, Oleuropein [49, 50] and Ginsensoside
[51] are also promising ones. Hence, these drugs might help to reduce the virulence of the
virus and can be considered for patients being treated for COVID -19. 
Conclusion:
In  this  study,  structure  based  virtual  screening  followed  by  the  validation  through
Molecular dynamic simulation approaches were carried out to find antiviral leads against
NSP15 of SARS-CoV-2. Thymopentin  (FDA-approved),  Ginsenoside,  and Oleuropein
were identified as potential inhibitors of NSP15. Molecular docking and MD simulations
investigated  the  binding  affinities,  mode  of  binding,  stability  of  binding  and  their
potential interactions. The drug leads identified in this study sheds light on the pandemic
infectious disease that currently lacks specific drugs and vaccines. Further investigations
will be carried out for these drugs to check their efficiency in vitro and in vivo. 
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Supplementary data
No Protein Ligands Reference MOE score
kcal/mol
1 NSP15 Withanoside X [16] -6.6530
2 NSP15 Saikosaponins [17] -7.8399
3 NSP15 Glycyrrhizic acid [18, 41, 42] -7.2673
4 NSP15 Lopinavir [18, 21, 22] -5.0902
5 NSP15 Ribavirin [18] -3.7347
6 NSP15 Glisoxepide [19] -5.0389
7 NSP15 Idarubicin [19] -5.5733
8 NSP15 quinadoline B [20] -4.0146
9 NSP15 Remedesivir [21,22] -5.5850
Table S1: Docking of NSP15 with the reported inhibitor and their estimated binding
affinities
No Ligands Tumori-
genicity
Irritant Drug
Likeness
CLogP CLogS LE
1. Thymopentin None None -2.0657 -8.3593 -2.129 0.17628
2. Oleuropein None None -7.1766 -0.3124 -1.768 0.22626
3. Ginsenoside None None -11.64 -0.1028 -4.833 0.10914
4. Kaempferitrin None None 1.9289 -0.1371 -3.387 0.20872
5. Rhoifolin None None 1.1329 -2.142 -2.949 0.20874
6. Demeclocyclin
hydrochloride
None None 2.8917 -4.6648 -2136 0.27149
7. Akebia
Saponin D
None None -12.698 0.2283 -4.85 0.12731
8. Liensinine None None 4.2826 4.0339 -5.513 0.18942
9. Fidaxomicin None None -2.7125 8.3037 -7.667 0.11386
10. Amikacin
hydrate
None None 2.5019 -21.186 0.233 0.21365
Table S2:  Various physico-chemical and predicted biological properties of NSP15 and the
lead compounds
Figure S1: Docking of NSP15 with the reported inhibitor and its interactions
